查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1530735

到 2030 年照护现场诊断市场预测：按产品类型、平台、配方、样品、应用、最终用户和地区进行的全球分析

Point-of-Care Diagnostics Market Forecasts to 2030 - Global Analysis By Product Type, Platform, Prescription, Sample, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2024 年全球照护现场诊断市场规模将达到 334 亿美元，预计到 2030 年将达到 535 亿美元，预测期内复合年增长率为 8.2%。

护理点 (POC) 诊断是在患者护理点或附近进行的医学测试。这种方法可以快速诊断和及时治疗，改善患者预后并减少后续观察需求。 POC诊断包括多种测试，包括血糖监测、怀孕检测、感染疾病检测和心臟标记。用于 POC 诊断的技术旨在用户友好，通常需要对医疗保健提供者和患者进行最少的培训。这些测试可快速提供结果，对于重症加护环境、远距环境和慢性病管理至关重要。 POC 诊断的便利性和速度有助于快速做出明智的临床决策并提高医疗服务的效率。

根据美国疾病管制与预防美国（CDC）2021年发布的资料，美国约有3,840万名糖尿病患者。

慢性疾病和感染疾病增加

由于人口老化、不健康的生活方式和环境变化等因素，糖尿病、癌症和心臟病等慢性病在世界各地变得越来越普遍。 POC 测试有助于早期发现和管理这些疾病。 COVID-19、HIV 和结核病等感染疾病也是主要驱动因素，POC 测试可以实现快速诊断和干预，从而促进市场成长。

严格的监管要求

严格的监管要求通常包括严格的测试、文件和核准流程，这些流程既耗时又昂贵。因此，公司可能会面临将新的 POC 诊断设备推向市场的延迟，从而阻碍创新并降低进步造福患者的速度。对于中小企业和新兴企业来说，达到监管标准的高昂成本尤其困难，并且会限制竞争力并抑制市场多样性。

转向分散式医疗保健

去中心化医疗模式专注于超越传统医院的范围，为病人提供更贴近的照护。因此，对快速、便携且易于使用的诊断工具的需求激增。 POC 诊断可以在患者所在的地方即时检测和决策，无论是在家中、在诊所还是在远端位置，这与分散式医疗保健的目标完全一致。这项转变将增加诊断服务的可近性，特别是在服务不足和农村地区，并减少对大型实验室基础设施的需求。

准确性和可靠性问题

与传统的临床测试相比，POC 诊断工具可以产生不同的结果。这种差异削弱了医疗保健专业人员和患者对 POC 诊断工具的信任，使他们不愿意传播这些工具。不准确或不一致的结果可能导致误诊、不适当的治疗计划，并最终导致患者预后不良，这是医疗机构的一个主要问题。此外，医疗保健提供者可能需要集中实验室进行额外的验证性测试来确认 POC 结果，这否定了快速诊断的主要好处。

COVID-19 的影响：

COVID-19 大流行对即时照护 (POC) 诊断市场产生了重大影响。对快速、准确和易于访问的测试解决方案的迫切需求导致对 POC 诊断工具的需求空前激增。政府和医疗保健系统已优先考虑进行 POC 测试，以快速检测和监测病毒，从而加速这些技术的创新和采用。监管机构也加快了核准流程，加快了市场准入速度。然而，供应链中断和对 COVID-19 诊断的集中努力暂时使其他疾病的 POC 测试的开发和可用性黯然失色。

血糖监测套件预计在预测期内将成为最大的细分市场

血糖监测套件对于糖尿病管理至关重要，体现了 POC 诊断的优势，可实现即时患者监测和即时决策，预计在预测期内将成长最快。该套件的广泛采用正在推动 POC 市场的技术进步和消费者接受度。此外，血糖监测套件的成功刺激了针对其他慢性病的类似 POC 诊断工具开发的创新和投资，从而扩大了市场并改善了整体医疗保健服务。

分子诊断领域预计在预测期内复合年增长率最高

分子诊断领域预计在预测期内复合年增长率最高。这是因为这些先进技术可以快速识别病原体的遗传物质，从而实现感染疾病、遗传性疾病和癌症的精确诊断。将分子诊断整合到 POC 中推动了创新，从而开发了可携式、用户友好的仪器，可以快速提供实验室品质的结果。这项进步扩大了 POC 诊断的应用，并透过及时介入改善了患者的治疗结果。

比最大的地区

由于慢性病盛行率高、人口老化以及对早期诊断和个人化医疗的重视，预计北美将在预测期内占据最大的市场占有率。该地区受益于先进的医疗基础设施、高额医疗支出以及强大的研发活动。此外，在美国和加拿大，POC 诊断越来越多地被引入各种环境，包括医院、诊所和居家医疗。 COVID-19 大流行进一步加速了对快速、准确的 POC 检测的需求，凸显了其在管理突发公共卫生事件和推动该地区市场成长的重要性。

复合年增长率最高的地区：

预计亚太地区在预测期内将维持最高复合年增长率。这是因为 FDA 等监管机构透过确保 POC 诊断设备的安全性和有效性，在塑造市场方面发挥重要作用。此外，人工智慧和行动医疗技术整合等技术进步正在推动创新并扩展 POC 诊断的能力。

提供免费客製化

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球照护现场市场：依产品类型

  • 血糖值监测套件
  • 传染病检查套件
  • 血液检测套组
  • 胆固醇检测套组
  • 怀孕/不孕症检测套组
  • 凝血监测套件
  • 尿液检查套件
  • 药物滥用检测套组
  • 心臟标记
  • 甲状腺刺激素测试
  • 血气/电解质
  • 其他产品类型

第六章全球照护现场诊断市场：按平台

  • 量油尺
  • 横向流动化验
  • 微流体
  • 分子诊断
  • 免疫检测
  • 其他平台

第七章 全球照护现场市场：按处方笺

  • 基于处方笺
  • 场外测试

第八章全球照护现场市场：按样本

  • 血
  • 鼻咽拭子
  • 尿
  • 其他样品

第九章全球照护现场市场：依应用分类

  • 感染疾病
  • 心臟病学
  • 糖尿病
  • 肿瘤学
  • 血液学
  • 怀孕和生殖
  • 胆固醇
  • 其他用途

第十章全球照护现场市场：依最终使用者分类

  • 医院
  • 诊所及门诊治疗中心
  • 居家照护设置
  • 诊断实验室
  • 学术研究所
  • 药局
  • 其他最终用户

第十一章全球照护现场市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十二章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十三章 公司概况

  • Abbott
  • AccuBioTech Co., Ltd
  • Anbio Biotechnology Co., Ltd.
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Chembio Diagnostics
  • Danaher Corporation
  • EKF Diagnostics
  • F. Hoffman-La Roche Ltd.
  • Instrumentation Laboratory
  • Nova Biomedical
  • Orasure Technologies, Inc.
  • PTS Diagnostics
  • Qiagen
  • Sekisui Diagnostics
  • Siemens Healthineers AG
  • Thermo Fisher Scientific
  • Trinity Biotech
  • Werfen
Product Code: SMRC26847

According to Stratistics MRC, the Global Point-of-Care Diagnostics Market is accounted for $33.4 billion in 2024 and is expected to reach $53.5 billion by 2030 growing at a CAGR of 8.2% during the forecast period. Point-of-Care (POC) Diagnostics are medical testing conducted at or near the site of patient care. This approach allows for rapid diagnosis and immediate treatment, enhancing patient outcomes and reducing the need for follow-up visits. POC diagnostics encompass a range of tests, including blood glucose monitoring, pregnancy tests, infectious disease detection, and cardiac markers. The technology used in POC diagnostics is designed to be user-friendly, often requiring minimal training for healthcare providers or even patients. These tests provide quick results, which are crucial in critical care settings, remote locations, and in managing chronic diseases. The convenience and speed of POC diagnostics help in making informed clinical decisions promptly, thus improving the efficiency of healthcare delivery.

According to 2021 data published by the Centers for Disease Control and Prevention (CDC), there are approximately 38.4 million people with diabetes in the U.S.

Market Dynamics:

Driver:

Rising prevalence of chronic and infectious diseases

Chronic diseases like diabetes, cancer, and heart disease are becoming increasingly common around the world, due to factors like aging populations, unhealthy lifestyles, and environmental changes. POC tests can help with early detection and management of these conditions. Infectious diseases like COVID-19, HIV, and tuberculosis are also a major driver, as POC tests enable rapid diagnosis and intervention which boosts the growth of the market.

Restraint:

Strict regulatory requirements

Strict regulatory requirements often involve rigorous testing, documentation, and approval processes that can be time-consuming and costly. Consequently, companies may face delays in bringing new POC diagnostic devices to market, hindering innovation and reducing the speed at which advancements can benefit patients. The high costs associated with meeting regulatory standards can be particularly challenging for smaller companies and startups, potentially limiting their ability to compete and stifling diversity in the market.

Opportunity:

Shift towards decentralized healthcare

Decentralized healthcare model emphasizes providing medical care closer to the patient, outside traditional hospital settings. As a result, the demand for rapid, portable, and easy-to-use diagnostic tools has surged. POC diagnostics enable immediate testing and decision-making at the patient's location, be it a home, clinic, or remote area, aligning perfectly with the goals of decentralized healthcare. This shift enhances accessibility to diagnostic services, especially in underserved and rural areas, reducing the need for extensive lab infrastructure.

Threat:

Accuracy and reliability concerns

POC diagnostic tools sometimes exhibit variability in results compared to traditional laboratory tests. This discrepancy can undermine healthcare professionals' and patients' confidence in these tools, leading to reluctance in their widespread adoption. Inaccurate or inconsistent results can result in misdiagnoses, inappropriate treatment plans, and ultimately poorer patient outcomes, which are critical concerns in medical practice. Moreover, healthcare providers may require additional confirmatory tests from centralized laboratories to verify POC results, counteracting the primary advantage of rapid diagnosis.

Covid-19 Impact:

The Covid-19 pandemic had a profound impact on the Point-of-Care (POC) Diagnostics market. The urgent need for rapid, accurate, and accessible testing solutions led to an unprecedented surge in demand for POC diagnostic tools. Governments and healthcare systems globally prioritized POC tests for quick detection and monitoring of the virus, accelerating innovation and adoption of these technologies. Regulatory bodies also expedited approval processes, allowing for faster market entry. However, supply chain disruptions and the intense focus on Covid-19 diagnostics temporarily overshadowed the development and availability of POC tests for other conditions.

The glucose monitoring kits segment is expected to be the largest during the forecast period

The glucose monitoring kits is expected to be the largest during the forecast period as these kits, essential for diabetes management, exemplify the benefits of POC diagnostics, enabling real-time monitoring and immediate decision-making for patients. Their widespread adoption has driven technological advancements and consumer acceptance in the POC market. Moreover, the success of glucose monitoring kits has spurred innovation and investment in developing similar POC diagnostic tools for other chronic conditions, thereby expanding the market and improving overall healthcare delivery.

The molecular diagnostics segment is expected to have the highest CAGR during the forecast period

The molecular diagnostics segment is expected to have the highest CAGR during the forecast period because these advanced techniques allow for the rapid identification of genetic material from pathogens, leading to precise diagnostics for infectious diseases, genetic disorders, and cancer. The integration of molecular diagnostics into POC settings has driven innovation, resulting in portable, user-friendly devices capable of delivering lab-quality results quickly. This advancement has expanded the applications of POC diagnostics, improved patient outcomes through timely intervention.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to high prevalence of chronic diseases, an aging population, and a strong emphasis on early diagnosis and personalized medicine. The region benefits from advanced healthcare infrastructure, significant healthcare expenditure, and robust research and development activities. Moreover in the United States and Canada, there is a strong adoption of POC diagnostics in various settings, including hospitals, clinics, and home care. The Covid-19 pandemic further accelerated the demand for rapid and accurate POC testing, highlighting its importance in managing public health emergencies drives the market growth in this region.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period because regulatory bodies like the FDA play a crucial role in shaping the market by ensuring the safety and efficacy of POC diagnostic devices. Additionally, technological advancements, such as the integration of artificial intelligence and mobile health technologies, are driving innovation and expanding the capabilities of POC diagnostics.

Key players in the market

Some of the key players in Point-of-Care Diagnostics market include Abbott, AccuBioTech Co., Ltd, Anbio Biotechnology Co., Ltd., Becton, Dickinson and Company, bioMerieux S.A., Chembio Diagnostics, Danaher Corporation, EKF Diagnostics, F. Hoffman-La Roche Ltd., Instrumentation Laboratory, Nova Biomedical, Orasure Technologies, Inc., PTS Diagnostics, Qiagen, Sekisui Diagnostics, Siemens Healthineers AG, Thermo Fisher Scientific, Trinity Biotech and Werfen

Key Developments:

In June 2024, Abbott and the National Association of Community Health Centers (NACHC) have joined together to increase access to healthy foods and improve health through the Innovation Incubator initiative.

In June 2024, BD (Becton, Dickinson and Company) and Edwards Lifesciences today announced a definitive agreement under which BD will acquire Edwards' Critical Care product group ("Critical Care"), for $4.2 billion in cash, unlocking new value creation opportunities and enhancing BD's portfolio of smart connected care solutions.

In March 2024, Abbott, Real Madrid and the Real Madrid Foundation announced the extension of their partnership through Real Madrid's 2026-27 seasons. Abbott will remain Global Health Sciences and Nutrition Partner of Real Madrid Football Club and Global Partner of the Real Madrid Foundation.

Product Types Covered:

  • Glucose Monitoring Kits
  • Infectious Disease Testing Kits
  • Hematology Testing Kits
  • Cholesterol Testing Kits
  • Pregnancy and Fertility Testing Kits
  • Coagulation Monitoring Kit
  • Urinalysis Testing Kits
  • Drug Abuse Testing Kits
  • Cardiac Markers
  • Thyroid Stimulating Hormone Testing
  • Blood Gas/Electrolytes
  • Other Product Types

Platforms Covered:

  • Dipsticks
  • Lateral Flow Assays
  • Microfluidics
  • Molecular Diagnostics
  • Immunoassays
  • Other Platforms

Prescriptions Covered:

  • Prescription Based
  • Over The Counter Testing

Samples Covered:

  • Blood
  • Nasal & Oropharyngeal Swabs
  • Urine
  • Other Samples

Applications Covered:

  • Infectious Diseases
  • Cardiology
  • Diabetes
  • Oncology
  • Hematology
  • Pregnancy & Fertility
  • Cholesterol
  • Other Applications

End Users Covered:

  • Hospitals
  • Clinics & Ambulatory Care Centers
  • Home Care Settings
  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Pharmacies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Point-of-Care Diagnostics Market, By Product Type

  • 5.1 Introduction
  • 5.2 Glucose Monitoring Kits
  • 5.3 Infectious Disease Testing Kits
  • 5.4 Hematology Testing Kits
  • 5.5 Cholesterol Testing Kits
  • 5.6 Pregnancy and Fertility Testing Kits
  • 5.7 Coagulation Monitoring Kit
  • 5.8 Urinalysis Testing Kits
  • 5.9 Drug Abuse Testing Kits
  • 5.10 Cardiac Markers
  • 5.11 Thyroid Stimulating Hormone Testing
  • 5.12 Blood Gas/Electrolytes
  • 5.13 Other Product Types

6 Global Point-of-Care Diagnostics Market, By Platform

  • 6.1 Introduction
  • 6.2 Dipsticks
  • 6.3 Lateral Flow Assays
  • 6.4 Microfluidics
  • 6.5 Molecular Diagnostics
  • 6.6 Immunoassays
  • 6.7 Other Platforms

7 Global Point-of-Care Diagnostics Market, By Prescription

  • 7.1 Introduction
  • 7.2 Prescription Based
  • 7.3 Over The Counter Testing

8 Global Point-of-Care Diagnostics Market, By Sample

  • 8.1 Introduction
  • 8.2 Blood
  • 8.3 Nasal & Oropharyngeal Swabs
  • 8.4 Urine
  • 8.5 Other Samples

9 Global Point-of-Care Diagnostics Market, By Application

  • 9.1 Introduction
  • 9.2 Infectious Diseases
  • 9.3 Cardiology
  • 9.4 Diabetes
  • 9.5 Oncology
  • 9.6 Hematology
  • 9.7 Pregnancy & Fertility
  • 9.8 Cholesterol
  • 9.9 Other Applications

10 Global Point-of-Care Diagnostics Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Clinics & Ambulatory Care Centers
  • 10.4 Home Care Settings
  • 10.5 Diagnostic Laboratories
  • 10.6 Academic & Research Institutes
  • 10.7 Pharmacies
  • 10.8 Other End Users

11 Global Point-of-Care Diagnostics Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Abbott
  • 13.2 AccuBioTech Co., Ltd
  • 13.3 Anbio Biotechnology Co., Ltd.
  • 13.4 Becton, Dickinson and Company
  • 13.5 bioMerieux S.A.
  • 13.6 Chembio Diagnostics
  • 13.7 Danaher Corporation
  • 13.8 EKF Diagnostics
  • 13.9 F. Hoffman-La Roche Ltd.
  • 13.10 Instrumentation Laboratory
  • 13.11 Nova Biomedical
  • 13.12 Orasure Technologies, Inc.
  • 13.13 PTS Diagnostics
  • 13.14 Qiagen
  • 13.15 Sekisui Diagnostics
  • 13.16 Siemens Healthineers AG
  • 13.17 Thermo Fisher Scientific
  • 13.18 Trinity Biotech
  • 13.19 Werfen

List of Tables

  • Table 1 Global Point-of-Care Diagnostics Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Point-of-Care Diagnostics Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 3 Global Point-of-Care Diagnostics Market Outlook, By Glucose Monitoring Kits (2022-2030) ($MN)
  • Table 4 Global Point-of-Care Diagnostics Market Outlook, By Infectious Disease Testing Kits (2022-2030) ($MN)
  • Table 5 Global Point-of-Care Diagnostics Market Outlook, By Hematology Testing Kits (2022-2030) ($MN)
  • Table 6 Global Point-of-Care Diagnostics Market Outlook, By Cholesterol Testing Kits (2022-2030) ($MN)
  • Table 7 Global Point-of-Care Diagnostics Market Outlook, By Pregnancy and Fertility Testing Kits (2022-2030) ($MN)
  • Table 8 Global Point-of-Care Diagnostics Market Outlook, By Coagulation Monitoring Kit (2022-2030) ($MN)
  • Table 9 Global Point-of-Care Diagnostics Market Outlook, By Urinalysis Testing Kits (2022-2030) ($MN)
  • Table 10 Global Point-of-Care Diagnostics Market Outlook, By Drug Abuse Testing Kits (2022-2030) ($MN)
  • Table 11 Global Point-of-Care Diagnostics Market Outlook, By Cardiac Markers (2022-2030) ($MN)
  • Table 12 Global Point-of-Care Diagnostics Market Outlook, By Thyroid Stimulating Hormone Testing (2022-2030) ($MN)
  • Table 13 Global Point-of-Care Diagnostics Market Outlook, By Blood Gas/Electrolytes (2022-2030) ($MN)
  • Table 14 Global Point-of-Care Diagnostics Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 15 Global Point-of-Care Diagnostics Market Outlook, By Platform (2022-2030) ($MN)
  • Table 16 Global Point-of-Care Diagnostics Market Outlook, By Dipsticks (2022-2030) ($MN)
  • Table 17 Global Point-of-Care Diagnostics Market Outlook, By Lateral Flow Assays (2022-2030) ($MN)
  • Table 18 Global Point-of-Care Diagnostics Market Outlook, By Microfluidics (2022-2030) ($MN)
  • Table 19 Global Point-of-Care Diagnostics Market Outlook, By Molecular Diagnostics (2022-2030) ($MN)
  • Table 20 Global Point-of-Care Diagnostics Market Outlook, By Immunoassays (2022-2030) ($MN)
  • Table 21 Global Point-of-Care Diagnostics Market Outlook, By Other Platforms (2022-2030) ($MN)
  • Table 22 Global Point-of-Care Diagnostics Market Outlook, By Prescription (2022-2030) ($MN)
  • Table 23 Global Point-of-Care Diagnostics Market Outlook, By Prescription Based (2022-2030) ($MN)
  • Table 24 Global Point-of-Care Diagnostics Market Outlook, By Over The Counter Testing (2022-2030) ($MN)
  • Table 25 Global Point-of-Care Diagnostics Market Outlook, By Sample (2022-2030) ($MN)
  • Table 26 Global Point-of-Care Diagnostics Market Outlook, By Blood (2022-2030) ($MN)
  • Table 27 Global Point-of-Care Diagnostics Market Outlook, By Nasal & Oropharyngeal Swabs (2022-2030) ($MN)
  • Table 28 Global Point-of-Care Diagnostics Market Outlook, By Urine (2022-2030) ($MN)
  • Table 29 Global Point-of-Care Diagnostics Market Outlook, By Other Samples (2022-2030) ($MN)
  • Table 30 Global Point-of-Care Diagnostics Market Outlook, By Application (2022-2030) ($MN)
  • Table 31 Global Point-of-Care Diagnostics Market Outlook, By Infectious Diseases (2022-2030) ($MN)
  • Table 32 Global Point-of-Care Diagnostics Market Outlook, By Cardiology (2022-2030) ($MN)
  • Table 33 Global Point-of-Care Diagnostics Market Outlook, By Diabetes (2022-2030) ($MN)
  • Table 34 Global Point-of-Care Diagnostics Market Outlook, By Oncology (2022-2030) ($MN)
  • Table 35 Global Point-of-Care Diagnostics Market Outlook, By Hematology (2022-2030) ($MN)
  • Table 36 Global Point-of-Care Diagnostics Market Outlook, By Pregnancy & Fertility (2022-2030) ($MN)
  • Table 37 Global Point-of-Care Diagnostics Market Outlook, By Cholesterol (2022-2030) ($MN)
  • Table 38 Global Point-of-Care Diagnostics Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 39 Global Point-of-Care Diagnostics Market Outlook, By End User (2022-2030) ($MN)
  • Table 40 Global Point-of-Care Diagnostics Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 41 Global Point-of-Care Diagnostics Market Outlook, By Clinics & Ambulatory Care Centers (2022-2030) ($MN)
  • Table 42 Global Point-of-Care Diagnostics Market Outlook, By Home Care Settings (2022-2030) ($MN)
  • Table 43 Global Point-of-Care Diagnostics Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 44 Global Point-of-Care Diagnostics Market Outlook, By Academic & Research Institutes (2022-2030) ($MN)
  • Table 45 Global Point-of-Care Diagnostics Market Outlook, By Pharmacies (2022-2030) ($MN)
  • Table 46 Global Point-of-Care Diagnostics Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.